摘要
目的:探讨曲妥珠单抗联合紫杉醇新辅助化疗人表皮生长因子受体2(HER2)阳性乳腺癌的效果。方法:选取2017年12月-2018年12月于本院进行治疗的HER2阳性乳腺癌患者60例,按照化疗药物不同分为对照组与研究组,每组30例。对照组采取曲妥珠单抗联合多西他赛化疗,研究组采取曲妥珠单抗联合紫杉醇化疗。比较两组治疗效果、不良反应及生活质量情况。结果:研究组治疗总有效率为93.33%高于对照组的70.00%(χ^2=5.455,P=0.020)。研究组发热与皮疹、严重中性粒细胞减少、轻度血红蛋白减少及疲倦发生率均低于对照组(P<0.05)。治疗前,两组各项生活质量评分比较,差异均无统计学意义(P>0.05);治疗后,研究组各项生活质量评分均高于对照组(P<0.05)。结论:曲妥珠单抗联合紫杉醇新辅助化疗HER2阳性乳腺癌患者效果较高,且不良反应较低,治疗后生活质量明显提升,值得应用。
Objective:To investigate the effect of Trastuzumab combined with Paclitaxel neoadjuvant chemotherapy for human epidermal growth factor receptor 2(HER2)positive breast cancer.Method:A total of 60 patients with HER2 positive breast cancer treated in our hospital from December 2017 to December 2018 were selected.According to different chemotherapeutic drugs,they were divided into control group and study group,30 cases in each group.The control group was treated with Trastuzumab and Docetaxel.The study group was treated with Trastuzumab and Paclitaxel.The treatment effect,adverse reactions and quality of life of the two groups were compared.Result:The total effective rate in the study group was 93.33%,higher than 70.00%in the control group(χ^2=5.455,P=0.020).The incidence of fever and rash,severe neutropenia,mild hemoglobin reduction and fatigue in the study group were lower than those in the control group(P<0.05).Before treatment,there were no significant differences in all quality of life scores between the two groups(P>0.05),after treatment,the all quality of life scores in the study group were higher than those in the control group(P<0.05).Conclusion:The efficacy of Trastuzumab combined with Paclitaxel neoadjuvant chemotherapy for HER2 positive breast cancer is higher,the adverse reactions are lower and the quality of life after treatment is significantly improved,which is worthy of application.
作者
李思锐
杨芳
张德慧
赫羽
LI Sirui;YANG Fang;ZHANG Dehui;HE Yu(Daqing Oilfield General Hospital,Daqing 163000,China)
出处
《中国医学创新》
CAS
2020年第3期5-8,共4页
Medical Innovation of China
